Abstract 173P
Background
Breast cancer (BC) presents challenges in predicting disease progression despite advancements in treatment and monitoring. Circulating tumor cells (CTCs) were initially seen as promising for prognosis via liquid biopsy, but complexities in their investigation have emerged over the past 15 years. Variability in isolation methods and the absence of universal CTC markers hinder standardization and comparison of research findings. In the present study we focused on CD24 which shows potential as a prognostic marker of BC. This study aims to elucidate the prognostic significance of CD24+ circulating cells in peripheral blood of BC patients.
Methods
The study included 57 patients with invasive breast carcinoma of no special type (IC NST) T1-4N0-3M0-1. Circulating cell phenotypes assessment was carried out by flow cytometry (Novocyte 3000, ACEA Biosciences, USA) using monoclonal antibody cocktail.
Results
In our investigation we utilized epithelial markers EpCAM and cytokeratin 7/8 to assess CTCs, including both metastatic and non-metastatic BC patients. Surprisingly, these markers were insufficient in identifying CTC populations indicative of distant metastasis in BC. However, we made the intriguing discovery of CD45-CD24+ circulating cells lacking epithelial markers EpCAM and CK7/8 associated with distant metastasis. Increased level of CD45-EpCAM-CK7/8-CD24+N-cadherin- circulating cells were observed among patients with established metastases and those who developed metastatic lesions during subsequent monitoring. Furthermore, exceeding a threshold of 218.3 cells per milliliter of peripheral blood before treatment predicted a 12-fold increase in metastatic risk and a 3-fold reduction in DMFS over a 90-month period. The unveiled cell population could originate with equal probability from epithelial cells that have undergone EMT or from immature cells from bone marrow. However, it should be noted that these CCs do not align with any recognized stages of monocyte or neutrophil maturation.
Conclusions
The count of CD45-EpCAM-CK7/8-CD24+N-cadherin- CCs was associated with distant metastasis, as their numbers were elevated in peripheral blood of patients with metastases during the follow-up period.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The study was supported by the Russian Science Foundation (grant #23-15-00135).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
193P - Translational, PK, PD, and immunophenotyping analyses of tuvusertib + niraparib in a phase Ib open-label multicenter dose-escalation study in patients with advanced solid tumors (DDRiver Solid Tumors 301)
Presenter: Anthony Tolcher
Session: Poster session 08
194P - CD8-to-CD20 lymphocyte ratio is a predictive biomarker for lenvatinib and pembrolizumab efficacy and progression-free survival in advanced endometrial cancer: Updated data
Presenter: Liubov Tashireva
Session: Poster session 08
195P - Preclinical efficacy of the trastuzumab duocarmazine SYD985 as monotherapy or in combination with the PARP inhibitor niraparib in HER2-expressing endometrial cancer
Presenter: Eva Colas
Session: Poster session 08
196P - Randomized phase II study of trabectedin/olaparib compared to physician’s choice in subjects with previously treated advanced or recurrent solid tumors harboring DNA repair deficiencies
Presenter: Richard Schlenk
Session: Poster session 08
197P - PRIME-ROSE: Merging clinical outcome data from DRUP-like clinical trials
Presenter: Tina Kringelbach
Session: Poster session 08
198P - Inavolisib in cancers with activating PIK3CA mutations: Results from the CRAFT trial
Presenter: Christoph Heilig
Session: Poster session 08
199P - Association of homologous recombination deficiency status with outcomes for ovarian cancer patients treated with olaparib, and exploration of other biomarkers of relapse and survival
Presenter: qingsheng xie
Session: Poster session 08
200P - Outcomes of patients (pts) with unfavourable, non-squamous cancer of unknown primary (CUP) progressing after induction chemotherapy (CTX) in the global, open-label, phase II CUPISCO study
Presenter: Tilmann Bochtler
Session: Poster session 08
201P - Efficacy of antibody drug conjugate (ADC) by mRNA expression of targeted genes in advanced solid tumors: SCRUM-Japan MONSTAR-SCREEN-2
Presenter: Takao Fujisawa
Session: Poster session 08